


9. The composition according to claim 7 wherein the immunosuppressant is selected from the group consisting of a cytotoxic agent, a corticosteroid, and a non-steroidal anti-inflammatory agent.
10. The composition according to claim 9, wherein the immunosuppressant is selected from the group consisting of cyclophosphamide, cyclosporin A, hydrocortisone, and dexamethasone.
11. The method according to claim 8, wherein the immunosuppressant is selected from the group consisting of a cytotoxic agent, a corticosteroid, and a non-steroidal anti-inflammatory agent.
12. The method according to claim 11, wherein the immunosuppressant is selected from the group consisting of cyclophosphamide, cyclosporin A, hydrocortisone, and dexamethasone.
13. A method of treatment or prophylaxis of a herpes simplex virus infection in a human in need thereof, which method comprises administering simultaneously to said human an effective amount of a nucleoside analogue active against herpes simplex virus selected from the group consisting of penciclovir and famciclovir, or a pharmaceutically acceptable salt or ester thereof and an effective amount of a pharmaceutically acceptable immunosuppressant.
14. The method according to claim 13, wherein the immunosuppressant is selected from the group consisting of a cytotoxic agent, a corticosteroid, and a non-steroidal anti-inflammatory agent.
15. The method according to claim 14, wherein the immunosuppressant is selected from the group consisting of cyclophosphamide, cyclosporin A, hydrocortisone, and dexamethasone.
16. A method of treatment or prophylaxis of herpes simplex virus infection in a human or animal in need thereof, which method comprises administering separately or sequentially to said human or animal an effective amount of a nucleoside analogue active against herpes simplex virus selected from the group consisting of penciclovir and famciclovir, or a pharmaceutically acceptable salt or ester thereof and an effective amount of a pharmaceutically acceptable immunosuppressant.
17. The method according to claim 16, wherein the immunosuppressant is selected from the group consisting of a cytotoxic agent, a corticosteroid, and a non-steroidal anti-inflammatory agent.

18. The method according to claim 17, wherein the immunosuppressant is selected from the group consisting of cyclophosphamide, cyclosporin A, hydrocortisone, and dexamethasone.
19. A pharmaceutical composition according to claim 7, wherein the composition is adapted for parenteral administration.
20. A pharmaceutical composition according to claim 7, wherein the composition is adapted for oral administration.
21. A method according to claim 8, wherein at least one of the nucleoside analogues or immunosuppressants is administered parenterally.
22. A method according to claim 8, wherein at least one of the nucleoside analogues or immunosuppressants is administered orally.

Applicant respectfully submits that the above claims are now in condition for allowance, which which action is earnestly solicited.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6938



Susan Hess
Attorney for Applicant
Reg. No. 37,350

Date: June 19, 2001